Ross D J, Marchevsky A, Kramer M, Kass R M
Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
J Heart Lung Transplant. 1997 Aug;16(8):832-8.
The clinical significance of an isolated "lymphocytic bronchiolitis/bronchitis" (grade B) as detected in transbronchoscopic biopsy specimens (TBB) is unclear. We therefore have reviewed the spirometric responses associated with isolated grade B diagnoses and contrasted them with episodes of "acute cellular rejection" (grade A); the latter are manifested by "perivascular lymphocytic infiltration." Because lymphocytic bronchiolitis/ bronchitis is considered a nonspecific histologic pattern that may be observed with either allograft rejection or respiratory infections, episodes were analyzed with respect to the presence (grade B [+] CMV) or absence (grade B [-] CMV) of cytomegalovirus infection. The maximum forced expiratory volume in 1 second (FEV1) during the preceding 3 months was used as a baseline for computing percent change in FEV1 coincident with transbronchoscopic biopsies (delta %FEV1 PRE) and maximum values obtained during the 3 months subsequent to specific therapies (delta %FEV1 POST). All episodes of acute cellular rejection (grades A1 to 4) and symptomatic lymphocytic bronchiolitis/bronchitis (grade B) were treated with "pulsed-dose" methylprednisolone, whereas intravenous ganciclovir was administered to patients at risk for recrudescence of cytomegalovirus. Between March 1, 1989, and September 1, 1995, 366 TBB procedures were performed for clinical indications in 57 lung transplant recipients. Histologic diagnoses with acceptable serial spirometric values included grade A1 (n = 9), grade A2 (n = 27), grade A3 (n = 2), grade B(-)CMV (n = 25) and grade B(+)CMV (n = 9). The delta %FEV1 PRE coincident with TBB were not statistically different for the different histologic groups. For grade A1, delta %FEV1 PRE was -14.6% +/- 5.2% (X +/- SEM); A2, -7.6% +/- 1.8%; B(-)CMV, -14.8% +/- 3.9%; and B(+)CMV, -14.8% +/- 2.3%. After treatment, the delta %FEV1 POST, relative to baseline values, were for grade A1, -8.8% +/- 7.1%, A2, +0.26% +/- 2.6%; B(-)CMV, -12.0% +/- 3.8%; and B(+)CMV, -6.2% +/- 2.8%. The delta %FEV1 POST values after pulsed methylprednisolone were significantly greater for histologic grade A2 than grade B(-)CMV (unpaired Student's t test, P < 0.01; 95% confidence interval for the difference of means: 3.34% to 21.2%). Grade A2 rejection was associated with spirometric improvement to within 10% of baseline values in 52% of episodes; whereas with grade B(-)CMV, this salutary response was observed in only 32% of episodes. Bronchiolitis obliterans syndrome stage 1b developed in 13 of 20 (65%) recipients, approximately 7.9 +/- 3.4 months after detection of histologic grade B and 21.2 +/- 9.5 months after transplantation. We conclude that the relative "refractoriness" of histologic grade B most likely reflects a continuum of bronchiolitis obliterans after lung transplantation and, hence, may warrant different immunosuppressive strategies. Furthermore, spirometric decrement associated with acute cellular rejection (grade A) may be ameliorated, but often not completely reversed, after pulsed methylprednisolone. We speculate that surveillance TBB may prove rewarding by enabling an earlier detection of these histologic diagnoses before the development of physiologic impairment.
经支气管镜活检标本(TBB)中检测到的孤立性“淋巴细胞性细支气管炎/支气管炎”(B级)的临床意义尚不清楚。因此,我们回顾了与孤立性B级诊断相关的肺功能测定反应,并将其与“急性细胞排斥反应”(A级)发作进行对比;后者表现为“血管周围淋巴细胞浸润”。由于淋巴细胞性细支气管炎/支气管炎被认为是一种非特异性组织学模式,可在同种异体移植排斥反应或呼吸道感染中观察到,因此根据巨细胞病毒感染的存在(B级[+]CMV)或不存在(B级[-]CMV)对发作进行分析。将前3个月内的1秒用力呼气量(FEV1)最大值作为基线,计算与经支气管镜活检同时出现的FEV1变化百分比(δ%FEV1 PRE)以及特定治疗后3个月内获得的最大值(δ%FEV1 POST)。所有急性细胞排斥反应发作(A1至4级)和有症状的淋巴细胞性细支气管炎/支气管炎(B级)均采用“脉冲剂量”甲泼尼龙治疗,而对有巨细胞病毒复发风险的患者给予静脉注射更昔洛韦。1989年3月1日至1995年9月1日期间,57例肺移植受者因临床指征进行了366次TBB检查。具有可接受的系列肺功能测定值的组织学诊断包括A1级(n = 9)、A2级(n = 27)、A3级(n = 2)、B(-)CMV级(n = 25)和B(+)CMV级(n = 9)。不同组织学组与TBB同时出现的δ%FEV1 PRE无统计学差异。对于A1级,δ%FEV1 PRE为-14.6%±5.2%(X±SEM);A2级为-7.6%±1.8%;B(-)CMV级为-14.8%±3.9%;B(+)CMV级为-14.8%±2.3%。治疗后,相对于基线值的δ%FEV1 POST,A1级为-8.8%±7.1%,A2级为+0.26%±2.6%;B(-)CMV级为-12.0%±3.8%;B(+)CMV级为-6.2%±2.8%。脉冲甲泼尼龙治疗后的δ%FEV1 POST值在组织学A2级显著高于B(-)CMV级(未配对学生t检验,P < 0.01;均值差异的95%置信区间:3.34%至21.2%)。52%的A2级排斥反应发作与肺功能改善至基线值的10%以内相关;而对于B(-)CMV级,仅32%的发作观察到这种有益反应。20例受者中有13例(65%)在检测到组织学B级后约7.9±3.4个月以及移植后21.2±9.5个月出现闭塞性细支气管炎综合征1b期。我们得出结论,组织学B级的相对“难治性”很可能反映了肺移植后闭塞性细支气管炎的连续性,因此可能需要不同的免疫抑制策略。此外,脉冲甲泼尼龙治疗后,与急性细胞排斥反应(A级)相关的肺功能下降可能会有所改善,但往往不能完全逆转。我们推测,监测TBB可能通过在生理功能受损之前更早地检测到这些组织学诊断而被证明是有价值的。